~ 0 7 Z qc/-5-SPECIAL-CAPNOSTREAM20-Two Parameter Monitor With A2 Software CONFIDENTIAL
4. 510(k) Summary of Safety and Effectiveness
This summary of safety and effectiveness information is being submitted in accordance with
the requirements of 21 CFR ยง 807.92 1 2
(This document is not confidential)
DATE THIS SUMMARY WAS PREPARED
August 15, 2007
SUBMITTER'S NAME AND ESTABLISHMENT ADDRESS:
Oridion Capnography Inc.
160 Gould Street
Needham, MA 02494
ESTABLISHMENT REGISTRATION NUMBER
3003941644
CONTACT PERSON:
Rachel Weissbrod, Director of Regulatory Affairs
Oridion Medical 1987 Ltd.
Har Hotzvim Science Park
POB 45025
91450 Jerusalem, Israel
Telephone: +972-2-589-9115
Fax: +972-2-586-6680
DEVICE INFORMATION
Trade Name: Capnostream 20with A2software
Common Name: Two Parameter Bedside Monitor
Classification Name: Capnograph/Pulse Oximeter
Regulation Number:
868.1400, Carbon Dioxide Analyzer (Classification CCK)
870.2700 Pulse Oximeter (Classification DQA)
Device Listing Number: B051971
Oridion Medical 1987 Ltd, 12SPECIAL-CAPNOSTREAM20-Two Parameter Monitor With A2 Software CONFIDENTIAL
PREDICATE DEVICE
Capnostream 20with the new miniMediCO 2module adaptive averaging (A2) software is
substantially equivalent to the following commercially available device:
Manufacturer Device 510(k)No. Clearance Date
Oridion 1987 Medical Capnostream 20K060065 May 4th, 2006
Ltd
DEVICE DESCRIPTION
The Capnostream 20bedside monitor is a two parameter monitor consisting of a
miniMediCO 2capnography module and a pulse oximetry module implemented in a host
device. The host device displays parameters received from the respective modules and
generates alarms when preset alarm thresholds are crossed. The device is classified as
CCK Class II according to 21 CFR ยง 868.1400 -Carbon Dioxide Analyzer.
This device has two modules that are classified as follows:
* 21 CFR 868.1400, Carbon Dioxide Analyzer (Classification CCK)
* 21 CFR870.2700 Pulse Oximeter (Classification DQA)
Each module is controlled by dedicated software that is an integral part of the
respective module. Each module provides parameters to the host software (the
Capnostream 20device software) which then controls the display of the received
parameter values and creates alarms when the values cross the preset thresholds.
The miniMediCO 2capnography module software presented in this submission
includes an adaptive averaging algorithm defined as the A2Algorithm for calculating
the respiration rate from the C02 waveform introduced in software version 2.31 of the
miniMediCO 2capnography module software. The calculated respiration rate
parameter is then provided to the host (the Capnostream 20device software). The host
makes no modification to the values received from the module. The host triggers an
alarm when the respiration rate high or respiration rate low thresholds have been
crossed. The algorithm employed in the respiration rate calculation reduces false
positive alarms by filtering out noise and instantaneous fluctuations without missing
true alarms that may indicate a clinically significant change to respiration rate. By
Oridion Medical 1987 Ltd. 13SPECIAL-CAPNOSTREAM20-Two Parameter Monitor With A2 Software CONFIDENTIAL
employing the adaptive averaging algorithm, the respiration rate accurately reflects the
patient's condition and significantly reduces the generation of nuisance alarms by the
host.
INTENDED USE
The Capnostream 20combined capnograph/pulse oximeter monitor is intended to provide
professionally trained health care providers the continuous, non invasive measurement and
monitoring of carbon dioxide concentration of the expired and inspired breath and
respiration rate, and for the continuous non-invasive monitoring of functional oxygen
saturation of arterial hemoglobin (SpO2) and pulse rate. It is intended for use with neonatal,
pediatric and adult patients in hospitals, hospital type facilities, intra hospital transport and
home environments.
COMPARISON TO PREDICATE DEVICE
The Capnostream 20 with adaptive averaging (A2) software (miniMediCO2 software version
2.31) is identical to the predicate Capnostream 2o (miniMediCO2 software version 2.20) with
the exception of the algorithm changes. No changes to the host (Capnostream 2o) software
were made to support the new module algorithms and no significant hardware changes
have been made to the device.
The new device meets the safety and performance standards met by the predicate device.
Test data are provided to validate the performance of the software and its substantial
equivalence to the predicate device. The functional features and the intended use of
Capnostream 20with adaptive averaging software are substantially equivalent to the
predicate device.
A hazard analysis was carried out on the module with the new algorithms. This hazard
analysis concluded that any residual risks were judged as acceptable when weighed
against the intended benefits of use of the system.
Attribute Capnostream 20Bedside Predicate Device- Capnostream 2o Bedside
Monitor with MiniMediCO 2Monitor K060065
EtCO2module with adaptive
averaging (A2) software
(version 2.31)
Indications for The indications for use are identical The Capnostream 20combined capnograph/pulse
use to the indications for use in the oximeter monitor is intended to provide
predicate device professionally trained health care providers the
continuous, non invasive measurement and
Oridion Medical 1987 Ltd. 14SPECIAL-CAPNOSTREAM20-Two Parameter Monitor With A2 Software CONFIDENTIAL
monitoring of carbon dioxide concentration of the
expired and inspired breath and respiration rate,
and for the continuous non-invasive monitoring of
functional oxygen saturation of arterial
hemoglobin (Sp02and pulse rate). It is intended
for use with neonatal, pediatric and adult patients
in hospitals, hospital type facilities, intra hospital
transport and home environments.
Target It is intended for use with neonatal, It is intended for use with neonatal, pediatric, and
population pediatric, and adult patients. adult patients.
Design Identical to MiniMediCO 2module in See K060065
K060065 with the exception of
software version change from 2.20
to 2.31
Where Used It is to be used by physicians, It is to be used by physicians, nurses and other
nurses and other trained health trained health care providers in critical care
care providers in critical care patient settings, such as anesthesiology,
patient settings, such as intensive care medicine, neonatal Intensive care
anesthesiology, intensive care and other health care areas
medicine, neonatal Intensive care
and other health care areas
Performance IS021647 IS021647
Standards ISO 9919 ISO 9919
Safety IEC/EN60601-1 IEC/EN60601-1
StandardsIEC/EN60601-1-2(2001) IEC/EN60601-1-2(2001)
IEC60601-1-8 IEC60601-1-8
UL60601-1 UL60601-1
ISO 14971 ISO 14971
Biocompatibility There are no issues of There are no issues of biocompatibility for this
biocompatibility for this device and device and no biocompatibility testing was done.
no biocompatibility testing was
done.
Sterility This device does not require This device does not require sterilization and is
sterilization and is shipped marked shipped marked non-sterile.
non-sterile.
CONCLUSION
Capnostream 20with adaptive averaging software does not raise any new potential safety
risks and is equivalent in performance to the existing legally marketed device. Therefore,
the device is substantially equivalent to the predicate device with respect to safety
effectiveness, and intended use.
Oridion Medical 1987 Ltd. 18DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration
9200 Corporate Boulevard
OCT .1 .[ 200? Rockville MD 20850
Oridion Capnography, Incorporated
C/O Ms. Rachel Weissbrod
Director of Regulatory Affairs
Oridion Medical 1987 Limited
Har Hotzvim Science Park
Post Office Box 45025
91450 Jerusalem
ISRAEL
Re: K072295
Trade/Device Name: Capnostream 20
Regulation Number: 21 CFR 870.2700
Regulation Name: Oximeter
Regulatory Class: II
Product Code: DQA, CCK
Dated: September 16, 2007
Received: September 20, 2007
Dear Ms. Weissbrod:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the
indications for use stated in the enclosure) to legally marketed predicate devices marketed in
interstate commerce prior to May 28, 1976, the enactment date of the Medical Device
Amendments, or to devices that have been reclassified in accordance with the provisions of
the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket
approval application (PMA). You may, therefore, market the device, subject to the general
controls provisions of the Act. The general controls provisions of the Act include
requirements for annual registration, listing of devices, good manufacturing practice,
labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III
(PMA), it may be subject to such additional controls. Existing major regulations affecting
your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In
addition, FDA may publish further announcements concerning your device in the Federal
Register.Page 2 -Ms. Weissbrod
Please be advised that FDA's issuance of a substantial equivalence determination does not
mean that FDA has made a determination that your device complies with other requirements
of the Act or any Federal statutes and regulations administered by other Federal agencies.
You must comply with all the Act's requirements, including, but not limited to: registration
and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice
requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if
applicable, the electronic product radiation control provisions (Sections 531-542 of the Act);
21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a
legally marketed predicate device results in a classification for your device and thus, permits
your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801),
please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation
entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You
may obtain other general information on your responsibilities under the Act from the
Division of Small Manufacturers, International and Consumer Assistance at its toll-free
number (800) 638-2041 or (240) 276-3150 or at its Internet address
http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Chiu Lin, Ph.D.
Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health
EnclosureSPECIAL-CAPNOSTREAM20-Two Parameter Monitor With A2 Software CONFIDENTIAL
3. Statement of Indications for Use
TWO PARAMETER CAPNOSTREAM20 MONITOR WITH ADAPTIVE AVERAGING
SOFTWARE
(This document is not confidential)
Indications for Use
August 15, 2007
510(k) Number (if known) -' O 7 d, .'J
Device Name: Capnostream 20
Indications For Use:
The Capnostream 20combined capnograph/pulse oximeter monitor is intended to provide
professionally trained health care providers the continuous, non invasive measurement and
monitoring of carbon dioxide concentration of the expired and inspired breath and
respiration rate, and for the continuous non-invasive monitoring of functional oxygen
saturation of arterial hemoglobin (SpO2and pulse rate). It is intended for use with neonatal,
pediatric and adult patients in hospitals, hospital type facilities, intra hospital transport and
home environments.
Prescription Use X AND/OR Over-The-Counter Use
(Per 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE -CONTINUE ON ANOTHER PAGE IF
NEEDED)
(Division Sign-0ff)
Division of Anesthesiology, General Hospital
Infection Control, Dental Devices
510(k) Number: /O %7 2 9
Oridion Medical 1987 Ltd.